Latest News and Press Releases

VERAXA Biotech initiates a collaboration with Ardigen SA to optimize cancer target pair selection for growing BiTAC® pipeline.

VERAXA Biotech AG today announced the appointment of Carl von Halem as as Interim Chief Financial Officer.

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”) today provided a company and pipeline update.

VERAXA Biotech announces further progress with lead BiTAC® T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM.

VERAXA Biotech has moved into additional laboratory space at its R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.

VERAXA Biotech AG (NASDAQ: VRXA) has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform.